VPT Ventripoint Diagnostics Ltd

Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) announces that
following the clearance by the US Food and Drug Administration (FDA) of the
VMS(TM) heart analysis system for right ventricle assessment in adult patients
with Pulmonary Arterial Hypertension (PAH), the Company has focused on advancing
marketing strategies, furthering partnership discussions for technology
integration and establishing clinical studies to broaden the application of the
VMS. We report today on the completion of two studies, one in PAH and one in
congenital heart disease. Both studies verify the utility of the VMS(TM) in
monitoring patients after treatment to determine if the therapy has been
effective. 


"The VMS(TM) is the first ultrasound system to be cleared as equivalent to MRI
for right ventricle analysis," said Dr. George Adams, President and CEO of
Ventripoint. "Now there is no need to wait to have an expensive MRI to
functionally evaluate the right ventricle. We continue to build value for the
Company by looking at all possible ways to market and advance the VMS(TM) with a
focus on the upcoming cardiology meetings in the United States."


Right heart function remains a significant prognostic parameter for all heart
disease. The recent clearance has paved the way to further our product's value
by expanding its application to all major heart conditions. We have developed a
regulatory strategy and although it is difficult to gauge timelines for FDA
processes, we anticipate utilizing the Special 510(k) process using the VMS(TM)
as the predicate device, and expect additional applications will be approved by
the 3rd quarter this year.


We are pleased to announce that at the 13th International Pulmonary Hypertension
Forum in Lisbon this week, Dr. Johannes Schwaiger of the Department of
Cardiology at Royal Free Hospital in London will be lecturing on his experiences
using the VMS(TM) to verify a significant change in RV ejection fraction after
novel targeted treatments, which resulted in significant improvements in
patients with PAH in a session entitled "Progress and future challenges in the
management of PAH". 


We are also pleased to report that the group at the Rikshospitalet University
Hospital in Oslo, Norway, led by Dr. Henrik Brun, has published a paper in the
Congenital Heart Disease Journal entitled "Right Ventricular Volumes Assessed by
Echocardiographic Three-dimensional Knowledge-based Reconstruction Compared with
Magnetic Resonance Imaging in a Clinical Setting". The paper reports on patients
with Congenital Heart Disease, who had undergone pulmonary valve replacement and
found excellent feasibility (97% of patients could be assessed) with VMS(TM) and
clinically useful correlations with MRI for RV volumes. The paper concludes with
the comment "Knowledge-based reconstruction (VMS) may replace MRI measurements
for serial follow-up...".


The VMS(TM) is approved for clinical use in PAH patients in Canada and Europe,
and now in the United States.


About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading
cause of death in developed countries. VMS(TM) is the first cost-effective and
accurate tool for measuring right ventricle heart function. The Corporation has
a suite of applications for all major heart diseases and imaging modalities
including congenital heart disease, left or right heart failure and normal
hearts - a multi-billion dollar market potential.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release


FORWARD-LOOKING STATEMENTS: The statements made in this news release that are
not historical facts may contain forward-looking information that involves risk
and uncertainties. All statements, other than statements of historical facts,
which address Ventripoint's expectations, should be considered forward-looking
statements. Such statements are based on management's exercise of business
judgment as well as assumptions made by and information currently available to
management. When used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue
reliance on these forward-looking statements. These statements reflect a current
view of future events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities regulatory
authorities. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking statements. A
description of assumptions used to develop such forward-looking information and
a description of risk factors that may cause actual results to differ materially
from forward-looking information can be found in Ventripoint's disclosure
documents on the SEDAR website at www.sedar.com. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Ventripoint Diagnostics Ltd.
Dr. George Adams
CEO
(206) 910-9125
gadams@ventripoint.com

Ventripoint Diagnostics (TSXV:VPT)
Historical Stock Chart
From Jan 2025 to Feb 2025

Ventripoint Diagnostics (TSXV:VPT)
Historical Stock Chart
From Feb 2024 to Feb 2025